Intra-arterial Prourokinase for Acute Ischemic Stroke: The PROACT II Study: A Randomized Controlled Trial | Cerebrovascular Disease | JAMA | JAMA Network
Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.206.238.77. Please contact the publisher to request reinstatement.
JAMA Network Home
JAMA
full text icon
Full Text
 contents icon
Contents
 figure icon
Figures /
Tables
 multimedia icon
Multimedia
 attach icon
Supplemental
Content
 references icon
References
 related icon
Related
 comments icon
Comments
1.
The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.  Tissue plasminogen activator for acute ischaemic stroke.  N Engl J Med.1995;333:1581-1587.Google Scholar
2.
Hacke W, Kaste M, Fieschi C.  et al.  Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS).  JAMA.1995;274:1017-1025.Google Scholar
3.
Donnan GA, Davis SM, Chambers BR.  et al.  Streptokinase for acute ischemic stroke with relationship to time of administration.  JAMA.1996;276:961-966.Google Scholar
4.
The Multicenter Acute Stroke Trial—Europe Study Group.  Thrombolytic therapy with streptokinase in acute ischemic stroke.  N Engl J Med.1996;335:145-150.Google Scholar
5.
The Multicenter Acute Stroke Trial–Italy (MAST–I) Group.  Randomised controlled trial of streptokinase, aspirin and combination of both in treatment of acute ischaemic stroke.  Lancet.1995;346:1509-1514.Google Scholar
6.
Hacke W, Kaste M, Fieschi C.  et al.  Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II).  Lancet.1998;352:1245-1251.Google Scholar
7.
Clark WM, Albers GW.for the ATLANTIS Stroke Investigators.  The Atlantis rt-PA (Alteplase) Acute Stroke Trial: final results [abstract].  Stroke.1999;30:234.Google Scholar
8.
Muir KW, Grosset DG. Neuroprotection for acute stroke: making clinical trials work.  Stroke.1999;30:180-182.Google Scholar
9.
Sandercock P, Hennerici MG, Orgogozo JM, Davis SM, Gorelick PB. Mega trials versus small trials in stroke. In: Fisher M, Bogousslavsky J, eds. Current Review of Cerebrovascular Disease. Boston, Mass: Butterworth-Heinemann; 1999:217-222.
10.
Gonner F, Remonda L, Mattle H.  et al.  Local intra-arterial thrombolysis in acute ischemic stroke.  Stroke.1998;29:1894-1900.Google Scholar
11.
del Zoppo GJ, Ferbert A, Otis S.  et al.  Local intra-arterial fibrinolytic therapy in acute carotid territory stroke: a pilot study.  Stroke.1988;19:307-313.Google Scholar
12.
Theron J, Courtheoux P, Casasco A.  et al.  Local intraarterial fibrinolysis in the carotid territory.  AJNR Am J Neuroradiol.1989;10:753-765.Google Scholar
13.
Mori E, Tabuchi M, Yoshida T.  et al.  Intracarotid urokinase with thromboembolic occlusion of the middle cerebral artery.  Stroke.1988;19:802-812.Google Scholar
14.
Zeumer H, Freitag HJ, Zanella F.  et al.  Local intra-arterial fibrinolytic therapy in patients with stroke: urokinase versus recombinant tissue plasminogen activator (r-TPA).  Neuroradiology.1993;35:159-162.Google Scholar
15.
Hacke W, Zeumer H, Ferbert A.  et al.  Intra-arterial thrombolytic therapy improves outcome in patients with acute vertebrobasilar occlusive disease.  Stroke.1988;19:1216-1222.Google Scholar
16.
Pessin M, del Zoppo GJ, Furlan AJ. Thrombolytic treatment in acute stroke: review and update of selective topics. In: Moskowitz MA, Caplan LR, eds. Cerebrovascular Diseases: Nineteenth Princeton Stroke Conference. Boston, Mass: Butterworth-Heinemann; 1995:409-418.
17.
del Zoppo GJ, Higashida RT, Furlan AJ.  et al.  PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke.  Stroke.1998;29:4-11.Google Scholar
18.
Kasai S, Arimura H, Nishida M, Suyama T. Primary structure of single-chain pro-urokinase.  J Biol Chem.1985;260:12382-12389.Google Scholar
19.
Pannell R, Gurewich V. Pro-urokinase: a study of its stability in plasma and of a mechanism for its selective fibrinolytic effect.  Blood.1986;44:217-228.Google Scholar
20.
Tebbe U, Windeler J, Boesl I.  et al.  Thrombolysis with recombinant unglycosylated single-chain urokinase-type plasminogen activator (saruplase) in acute myocardial infarction: influence of heparin on early patency rate (LIMITS Study).  J Am Coll Cardiol.1995;26:365-373.Google Scholar
21.
Gurewich V, Liu J. Intra-arterial pro-urokinase in ischemic stroke [letter].  Stroke.1998;29:1255.Google Scholar
22.
Brott T, Adams Jr HP, Olinger CP.  et al.  Measurements of acute cerebral infarction: a clinical examination scale.  Stroke.1989;20:864-870.Google Scholar
23.
TIMI Study group.  Special report: the Thrombolysis in Myocardial Infarction (TIMI) trial.  N Engl J Med.1985;312:932-936.Google Scholar
24.
Wolfe CD, Taub NA, Woodrow BA, Burney PG. Assessment of scales of disability and handicap for stroke patients.  Stroke.1991;22:1242-1244.Google Scholar
25.
van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJA, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients.  Stroke.1988;19:604-607.Google Scholar
26.
Furlan AJ. Natural history of atherothromboembolic occlusion of cerebral arteries: carotid versus vertebrobasilar territories. In: Hacke W, del Zoppo GJ, Hirschberg M, eds. Thrombolytic Therapy in Acute Ischemic Stroke. New York, NY: Springer-Verlag; 1991:71-76.
27.
del Zoppo GJ, Poeck K, Pessin MS.  et al.  Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke.  Ann Neurol.1992;32:78-86.Google Scholar
28.
Ferguson RD, Ferguson JG. Cerebral intraarterial thrombolysis at the crossroads: is a phase III trial advisable at this time?  AJNR Am J Neuroradiol.1994;15:1201-1216.Google Scholar
29.
del Zoppo GJ, Higashida RT, Furlan AJ. The case for a phase III trial of cerebral intraarterial fibrinolysis.  AJNR Am J Neuroradiol.1994;15:1217-1222.Google Scholar
30.
Moulin T, Cattin F, Crepin-Leblond T.  et al.  Early CT signs in acute middle cerebral artery infarction: predictive value for subsequent infarct locations and outcome.  Neurology.1996;47:366-375.Google Scholar
31.
von Kummer R, Allen KL, Holle R.  et al.  Acute stroke: usefulness of early CT findings before thrombolytic therapy.  Radiology.1997;205:327-333.Google Scholar
32.
Toni D, De Michele M, Fiorelli M.  et al.  Influence of hyperglycemia on infarct size and clinical outcome of acute ischemic stroke patients with intracranial arterial occlusion.  J Neurol Sci.1994;123:129-133.Google Scholar
33.
Lodder J, Krijne-Kubat B, Broekman J. Cerebral hemorrhagic infarction at autopsy: cardiac embolic causes and the relationship to cause of death.  Stroke.1986;17:626-629.Google Scholar
34.
Hornig CR, Dorndorf W, Agnoli AL. Hemorrhagic cerebral infarction—a prospective study.  Stroke.1986;17:179-185.Google Scholar
35.
Okada Y, Yamaguchi T, Minematsu K.  et al.  Hemorrhagic transformation in cerebral embolism.  Stroke.1989;20:598-603.Google Scholar
36.
The NINDS t-PA Stroke Study Group.  Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke.  Stroke.1997;28:2109-2118.Google Scholar
37.
Wolpert SM, Bruckmann H, Greenlee R.  et al.  Neuroradiology evaluation of patients with acute stroke treated with recombinant tissue plasminogen activator.  AJNR Am J Neuroradiol.1993;14:3-13.Google Scholar
38.
Genentech, applicant.  Summary basis for approval: activaseTM for acute ischemic stroke. New Drug Application. PLA96-0350.
39.
Tomsick T, Brott T, Barsan W.  et al.  Prognostic value of the hyperdense middle cerebral artery sign and stroke scale score before ultraearly thrombolytic therapy.  AJNR Am J Neuroradiol.1996;17:79-85.Google Scholar
40.
Marler JR, Jones PW, Emr M. Rapid Identification and Treatment of Acute Stroke: Proceedings of a National Symposium. Bethesda, Md: National Institutes of Health; 1997. NIH Publication 97-439.
41.
Ueda T, Sakaki S, Nochide I.  et al.  Angioplasty after intra-arterial thrombolysis for acute occlusion of intracranial arteries.  Stroke.1998;29:2568-2574.Google Scholar
42.
Emergency Management of Stroke (EMS) Investigators.  Combined intra-arterial and intravenous tPA for stroke [abstract].  Stroke.1997;28:273.Google Scholar
43.
Pannell R, Black J, Gurewich V. The complementary modes of action of tissue plasminogen activator (t-PA) and pro-urokinase (pro-UK) by which their synergistic effect on clot lysis may be explained.  J Clin Invest.1988;81:853-859.Google Scholar
44.
Fisher M, Garcia JH. Evolving stroke and the ischemic penumbra.  Neurology.1996;47:884-888.Google Scholar
45.
Baron JC, von Kummer R, del Zoppo GJ. Treatment of acute ischemic stroke—challenging the concept of a rigid and universal time window.  Stroke.1995;26:2219-2221.Google Scholar
46.
Fisher M, Prichard JW, Warach S. New magnetic resonance techniques for acute ischemic stroke.  JAMA.1995;274:908-911.Google Scholar
47.
Staroselskaya IA, Baird AE, Linfante I.  et al.  Correlations between MR diffusion-perfusion studies and MRA in acute stroke.  Neurology.1999;52(suppl 2):455.Google Scholar
This Issue
Citations 2,179
View Metrics
Original Contribution
December 1, 1999

Intra-arterial Prourokinase for Acute Ischemic Stroke: The PROACT II Study: A Randomized Controlled Trial

Anthony Furlan, MD; Randall Higashida, MD; Lawrence Wechsler, MD; et al Michael Gent, DSc; Howard Rowley, MD; Carlos Kase, MD; Michael Pessin, MD; Arvind Ahuja, MD; Fred Callahan, MD; Wayne M. Clark, MD; Frank Silver, MD; Frank Rivera, MD; for the PROACT Investigators
Author Affiliations

Author Affiliations: Cerebrovascular Center, Department of Neurology, Cleveland Clinic Foundation, Cleveland, Ohio (Dr Furlan). Department of Neuroradiology, University of California, San Francisco (Drs Higashida and Rowley); Stroke Institute, University of Pittsburgh, Pittsburgh, Pa (Dr Wechsler); Department of Clinical Epidemiology and Biostatistics, McMaster University and Clinical Trials Methodology Group, Hamilton Civic Hospital Research Center, Hamilton, Ontario (Dr Gent); Department of Neurology, Boston University School of Medicine (Dr Kase), Department of Neurology, New England Medical Center (Dr Pessin), Boston, Mass; Department of Neurosurgery, St Lukes' Medical Center, Milwaukee, Wis (Dr Ahuja); Neurologic Consultants PC, Centennial Medical Center, Nashville, Tenn (Dr Callahan); Department of Neurology, Oregon Health Sciences University, Portland (Dr Clark); Department of Neurology, The Toronto Hospital–Western Division, Toronto, Ontario (Dr Silver); and Department of Vascular and Interventional Radiology, Baylor University Medical Center, Dallas, Tex (Dr Rivera). Dr Pessin is deceased.

JAMA. 1999;282(21):2003-2011. doi:10.1001/jama.282.21.2003
visual abstract icon
Visual
Abstract
 editorial comment icon
Editorial
Comment
 related articles icon
Related
Articles
 author interview icon
Interviews
 multimedia icon
Multimedia
Abstract

Context Intravenous tissue-type plasminogen activator can be beneficial to some patients when given within 3 hours of stroke onset, but many patients present later after stroke onset and alternative treatments are needed.

Objective To determine the clinical efficacy and safety of intra-arterial (IA) recombinant prourokinase (r-proUK) in patients with acute stroke of less than 6 hours' duration caused by middle cerebral artery (MCA) occlusion.

Design PROACT II (Prolyse in Acute Cerebral Thromboembolism II), a randomized, controlled, multicenter, open-label clinical trial with blinded follow-up conducted between February 1996 and August 1998.

Setting Fifty-four centers in the United States and Canada.

Patients A total of 180 patients with acute ischemic stroke of less than 6 hours' duration caused by angiographically proven occlusion of the MCA and without hemorrhage or major early infarction signs on computed tomographic scan.

Intervention Patients were randomized to receive 9 mg of IA r-proUK plus heparin (n = 121) or heparin only (n = 59).

Main Outcome Measures The primary outcome, analyzed by intention-to-treat, was based on the proportion of patients with slight or no neurological disability at 90 days as defined by a modified Rankin score of 2 or less. Secondary outcomes included MCA recanalization, the frequency of intracranial hemorrhage with neurological deterioration, and mortality.

Results For the primary analysis, 40% of r-proUK patients and 25% of control patients had a modified Rankin score of 2 or less (P = .04). Mortality was 25% for the r-proUK group and 27% for the control group. The recanalization rate was 66% for the r-proUK group and 18% for the control group (P<.001). Intracranial hemorrhage with neurological deterioration within 24 hours occurred in 10% of r-proUK patients and 2% of control patients (P = .06).

Conclusion Despite an increased frequency of early symptomatic intracranial hemorrhage, treatment with IA r-proUK within 6 hours of the onset of acute ischemic stroke caused by MCA occlusion significantly improved clinical outcome at 90 days.

×